Korro Bio (NASDAQ:KRRO) Stock Rating Reaffirmed by BMO Capital Markets

BMO Capital Markets reiterated their outperform rating on shares of Korro Bio (NASDAQ:KRRO) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $120.00 price objective on the stock.

A number of other equities research analysts have also recently commented on KRRO. HC Wainwright reaffirmed a buy rating and issued a $100.00 price target on shares of Korro Bio in a report on Friday, January 19th. Royal Bank of Canada initiated coverage on Korro Bio in a research note on Wednesday, November 29th. They issued an outperform rating and a $70.00 target price on the stock.

Korro Bio Trading Up 1.7 %

Shares of KRRO stock opened at $90.00 on Tuesday. The company has a market capitalization of $66.60 million, a price-to-earnings ratio of -0.95 and a beta of 2.09. Korro Bio has a 52 week low of $9.15 and a 52 week high of $97.91. The stock has a 50-day moving average of $56.31.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC bought a new position in shares of Korro Bio in the fourth quarter worth $53,648,000. Eventide Asset Management LLC purchased a new stake in Korro Bio during the 4th quarter worth about $26,185,000. 72 Investment Holdings LLC bought a new position in Korro Bio in the 4th quarter worth about $13,269,000. Vanguard Group Inc. purchased a new position in Korro Bio during the 4th quarter valued at about $12,988,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Korro Bio during the fourth quarter valued at about $12,741,000. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.